Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study

Article ID	Journal	Published Year	Pages	File Type
5590849	Multiple Sclerosis and Related Disorders	2017	37 Pages	PDF

Abstract

Patients reported high treatment satisfaction with teriflunomide, with switchers also reporting improved treatment satisfaction vs baseline. High treatment satisfaction in patients with RMS may lead to improved adherence, and hence treatment outcomes.

Keywords

RRMs nonsignificant MusiQoL TSQM Relapsing-remitting MS PDDS SDMT MSPs Symbol Digit Modalities Test MedDRA DMTs EDSS ALT DMF RMS Quality of life Aes Alanine aminotransferase standard deviation Effect size teriflunomide baseline disease-modifying therapies Disease-modifying therapy dimethyl fumarate Medical Dictionary for Regulatory Activities Treatment satisfaction Spearman's rank correlation coefficient Adverse events confidence interval Expanded Disability Status Scale Multiple sclerosis Patient-reported outcomes patient-reported outcome PRO

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Genetics

Preview

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study

Authors

Patricia K. Coyle, Bhupendra Khatri, Keith R. Edwards, José E. Meca-Lallana, Steve Cavalier, Pascal Rufi, Myriam Benamor, Sandrine Brette, Miqun Robinson, Ralf Gold, for the Teri-PRO Trial Group for the Teri-PRO Trial Group,